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Abstract: The biodiversity of the marine environment and the associated chemical 
diversity constitute a practically unlimited resource of new antitumor agents in the field of 
the development of marine bioactive substances. In this review, the progress on studies of 
antitumor peptides from marine sources is provided. The biological properties and 
mechanisms of action of different marine peptides are described; information about their 
molecular diversity is also presented. Novel peptides that induce apoptosis signal pathway, 
affect the tubulin-microtubule equilibrium and inhibit angiogenesis are presented in 
association with their pharmacological properties. It is intended to provide useful 
information for further research in the fields of marine antitumor peptides. 
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1. Introduction 
The sea, covering 70% of the Earth’s surface, offers a considerably broader spectrum of biological 
diversity than terra firma. Containing approximately 75% of all living organisms, the marine 
environment offers a rich source of natural products with potential therapeutic application. The 
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discovery of the bio-regulatory role of different endogenous peptides in the organism as well as the 
understanding of the molecular mechanisms of action about some new bioactive peptides obtained 
from natural sources on specific cellular targets, contributed to developing peptides as promising lead 
drug candidates. Recently, marine peptides have opened a new perspective for pharmaceutical 
developments [1]. 
Peptides discovered from marine organism induce cell death with different mechanisms, including 
apoptosis, affecting the tubulin-microtubule equilibrium, or inhibiting angiogenesis (Figure 1). This 
finding has increased our knowledge about new potent cytotoxic, and many other properties with novel 
chemical structures associated to original mechanisms of pharmacological activity. These facts 
introduce marine peptides as a new choice for obtaining lead compounds on biomedical research. This 
review will account for the progress of the recent years and provide novel information in this field. 
Figure 1. Schematic depiction of major mechanisms for major antitumor peptides.   
Marine peptides induce cell death via the following pathways, apoptosis (1), affecting the 
tubulin-microtubule equilibrium (2) and angiogenesis pathway (3). 
 
2. Peptides that Induce Apoptosis 
Apoptosis as a form of programmed cell death is one of the major mechanisms of cell death in 
response to cancer therapies [2]. Also, apoptosis is a naturally occurring and evolutionarily conserved 
process by which cells that are no longer useful are directed to their deaths [3]. Apoptosis plays an 
indispensable role and is a fundamental process in development, physiology and homeostasis [4–7]. Its 
deregulation, i.e., either loss of pro-apoptotic signals or gain of anti-apoptotic signals, can lead to a 
variety of pathological conditions such as cancer initiation, promotion and progression or result in 
treatment failures [8,9]. As apoptosis does not usually trigger inflammatory or immune response, it Mar. Drugs 2011, 9 
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becomes a preferable way of cancer cell death during cancer treatments. As such, modulation of 
apoptotic pathways and selective induction of apoptosis by chemical agents are likely to be a 
promising approach for cancer therapy [6,10–15]. In mammals, there are two major signaling systems 
that result in the activation of caspases, the extrinsic death receptor pathway [16–19] and the intrinsic 
mitochondrial pathway [20,21]. These two pathways include many cross talks between them. There is 
a long list of pro- or anti-apoptotic molecules that can trigger or regulate apoptosis. Therefore, 
developing anticancer peptides that target these molecules has become an important strategy for 
anticancer therapies. 
Growing evidence shows that most marine anticancer peptides with cytotoxicity may trigger 
apoptosis by targeting many cellular proteins, and the induced apoptotic process involves both 
intracellular and extracellular pathways [14]. The balance between the pro-survival gene Bcl-2 and the 
pro-apoptotic gene Bax plays a key role in maintaining cell viability. Therefore, inhibition of Bcl-2 or 
induction of Bax becomes a good strategy for triggering an apoptotic process [22]. Identification of 
caspases activators becomes another approach for the discovery of novel anticancer agents because 
caspases are involved in intrinsic and extrinsic apoptosis pathways [23,24]. Some marine anticancer 
peptides can activate the Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases 
(MAPK) pathways that lead to the release of cytochrome c (Cyt C) from mitochondria [25]. In brief, 
apoptosis is a complicated process and involves a huge number of signaling molecules, and failure of 
apoptosis activation is one of the major impediments to the treatment of cancer. Therefore, a good 
strategy for the development of new anticancer agents is to identify or develop such agents that can 
target multiple apoptosis regulating genes. 
2.1. Peptides that Activate the Intrinsic Mitochondrial Pathway 
The mitochondrial cell death pathway commences when apoptogenic molecules presented between 
the outer and inner mitochondrial membranes are released into the cytosol by mitochondrial outer 
membrane permeabilization. The release of pro-apoptotic factors such as cytochrome c from 
mitochondria leads to formation of a multimeric complex known as the apoptosome and initiates 
caspases activation cascades. These pathways are important for normal cellular homeostasis and play 
key roles in the pathogenesis of many diseases [21,26]. In the intrinsic mitochondrial pathway, at least 
18 pro- and anti-apoptotic proteins of the Bcl-2 family are pivotal regulators of apoptosis, Bax as a 
proapoptotic member of the Bcl-2 family is very influential in the pro- and anti-apoptotic balance by 
regulating mitochondrial functions [22,27]. 
Jaspamide (Jasplakinolide), isolated from marine sponge Jaspis johnstoni, is a cyclic depsipeptide 
with a 15-carbon macrocyclic ring containing three amino acid residues (Figure 2A) [28]. Jasplakinolide 
induces apoptosis in Jurkat T cells as demonstrated by nucleosomal DNA ladder formation. Enhanced 
caspase-3 activity is also observed in Jaspamide-treated Jurkat T cells by using the fluorescent 
substrate DEVD-MAC. Transformed cell lines were more susceptible to Jasplakinolide-induced 
apoptosis than normal nontransformed cells [29]. Jaspamide-induced apoptosis is associated with 
caspase-3 activation and a decrease in Bcl-2 protein expression, but also with increased Bax levels. It 
seems that jaspamide induces a caspases independent pathway of cell death, which is responsible for Mar. Drugs 2011, 9 
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the observed cytoplasmic and membrane changes in apoptosing cells, and also a caspases-dependent 
cell death, which is responsible for PARP proteolysis [30].  
Figure 2. Chemical structures of  major marine peptides with apoptotic activity: 
Jasplakinolide (A), Somocystinamide A (B), Aplidine (C) and Didemnin B (D). 
 
Some other peptides from marine sources, such as Somocystinamide A [31,32] and   
C-phycocyanin (C-PC) [33,34] have been observed to display potent caspases-dependent   
anti-apoptotic activity in different cancer cells. Somocystinamide A (ScA), a lipopeptide, was isolated 
from Lyngbya majuscula/Schizothrix sp. assemblage of marine cyanobacteria (Figure 2B) [31]. ScA 
stimulates apoptosis in a number of tumor cell lines and in angiogenic endothelial cells via both the 
intrinsic and extrinsic pathways, but the more effective mechanism is the activation of caspase-8 and 
its downstream pathways [32]. C-phycocyanin, a tetrapyrrole-protein complex isolated from the 
cyanobacteria Agmenellum quadruplicatum, Mastigocladus laminosus [33] and Spirulina platensis, 
could induce the activation of pro-apoptotic gene and down-regulation of anti-apoptotic gene 
expression, then facilitate the transduction of apoptosis signals that result in the apoptosis of HeLa 
cells in vitro. Caspases 2, 3, 4, 6, 8, 9, and 10 were activated in C-PC-treated HeLa cells, suggesting 
that C-PC-induced apoptosis was caspases-dependent. C-PC treatment of HeLa cells also results in 
release of cytochrome c from the mitochondria into the cytosol that was related to apoptosis of   
C-PC-treated HeLa cells [34]. Mar. Drugs 2011, 9 
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2.2. Peptides that Target the JNK or p38 MAPK Pathway 
Jun  N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases (MAPKs) play   
critical roles in the signaling mechanisms that orchestrate cellular responses to various types of cellular 
stress [35,36]. Unscheduled proliferation is a hallmark of cancer, and the JNK and p38 MAPK 
pathways regulate cell cycle progression at different points by both transcription-dependent and 
transcription-independent mechanisms, with profound effects on the development of various cancers. 
The pro- and anti-apoptotic effects of JNKs seem to be dependent not only on the stimuli, but also on 
the strength of the signals. Activation of the JNK and p38 MAPK pathways can trigger cytochrome c 
release and subsequently activate caspases cascades [35]. 
Aplidine (dehydrodidemnin B, DDB, Aplidin), a cyclic depsipeptide (Figure 2C), was isolated from 
the Mediterranean tunicate Aplidium albicans. Breast, melanoma and non-small-cell lung cancer 
appear to be sensitive to low concentrations of Aplidine [37,38]. Aplidine’s mechanism of action 
involves several pathways, including cell cycle arrest, inhibition of protein synthesis. Aplidine induces 
early oxidative stress and results in a rapid and persistent activation of JNK and p38 MAPK 
phosphorylation with activation of both kinases occurring very rapid, long before the execution of 
apoptosis, and full activation within 5–10 min of drug treatment in human HeLa tumor cells. JNK and 
p38 MAPK activation results in downstream cytochrome c release and activation of caspases-9 and -3 
and PARP cleavage, demonstrating the mediation of the mitochondrial apoptotic pathway in this process. 
Protein kinase C delta (PKC-d) mediates the cytotoxic effect of Aplidin and that it is concomitantly 
processed and activated late in the apoptotic process by a caspases mediated mechanism [39]. Aplidin 
induces apoptosis in MDA-MB-231 breast cancer cells, resulting in sustained activation of the 
epidermal growth factor receptor (EGFR), the non-receptor protein-tyrosine kinase Src, and the 
serine/threonine kinases JNK and p38 MAPK. Two mechanisms by which Aplidin activates JNK: 
rapid activation of Rac1 small GTPase and down regulation of MKP-1 phosphatase. Aplidine, also 
called plitidepsin in clinical trials, is well-tolerated with minor toxicity in finished Phase I clinical 
trials [40–42]. Phase II studies are underway [43]. 
2.3. Peptides with an Unknown Mechanism of Apoptosis-Inducing Activity 
Some marine peptides are known to induce cell death with apoptotic characteristics, including DNA 
fragmentation, nucleic shrinking and cell membrane swelling. However, the exact mode of action of 
cytotoxicity is unclear. Didemnins, originally reported in 1981 [44,45], are a family of depsipeptides 
with antitumor, antiviral and immunosuppressive activities primarily isolated from the Caribbean 
tunicate  Trididemnum solidum, but later obtained from other species of the same genus [46,47]. 
Didemnin B, a branched N-methylated cyclic peptolide, originally was isolated from the Trididemnum 
genus of marine tunicates (Figure 2D). Didemnin B induces death of a variety of transformed cells 
with apoptotic morphology and DNA fragmentation within the cytosol and the generation of DNA 
ladders [48], but the exact mechanism for these effects is still obscure [49]. Until today, a lot of 
Didemnin analogues have been prepared semisynthetically and their biological activities evaluated, 
including cytotoxicity and antiviral and immunosuppressive properties [46,50]. However, Didemnin B Mar. Drugs 2011, 9 
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continues to be a main focus in clinical investigation, being the first marine natural product currently in 
clinical trials as an anti-cancer agent [51,52]. 
Some other peptides from marine sources, such as Sansalvamide A [53,54], Cycloxazoline [55,56] 
and virenamides A–C [57] have been observed to display potent anti-apoptotic activity in different 
cancer cells but the exact targets by these chemicals have not yet been identified. Sansalvamide A, a 
cyclic depsipeptide produced by a marine fungus, has demonstrated significant anticancer activity [54]. 
One of Sansalvamide A analogs caused G (1) phase cell cycle arrest in two human pancreatic cancer 
cell lines (AsPC-1 and CD18); Sansalvamide A, an inhibitor of topoisomerase I, induces cell death 
with only some apoptotic characteristics in some cancer cells [53]. Cycloxazoline, a new cyclic 
hexapeptide is reported from a marine ascidian Lissoclinum bistratum [55]. Accumulation of HL-60 
leukemia cells in G2/M and inhibition of cytokinesis was caused by cycloxazoline [56]. Three new 
linear cytotoxic tripeptides, virenamides A–C have been isolated from didemnid ascidian Diplosoma 
virens  [57]. The virenamides showed modest cytotoxicity towards a panel of cultured cells: 
Virenamide A gave IC50 of 2.5 μg/mL against P388, and 10 μg/mL against A549, HT29 and CV1 
cells, and exhibited topoisomerase II inhibitory activity. Virenamides B and C both gave IC50 of   
2.5 μg/mL against P388, A549, HT29, and CV1 cells [57]. 
3. Peptides that Affect the Tubulin-Microtubule Equilibrium 
Microtubules are intracellular organelles formed from the protein tubulin. These organelles have a 
number of essential cellular functions including chromosome segregation, the maintenance of cell 
shape, transport, motility, and organelle distribution. Drugs that affect the tubulin-microtubule 
equilibrium are effective anticancer drugs [58]. Tubulin binding molecules have generated 
considerable interest after the successful introduction of the taxanes into clinical oncology and the 
widespread use of the Vinca alkaloids Vincristine and Vinblastine. These compounds inhibit cell 
mitosis by binding to the protein tubulin in the mitotic spindle and preventing polymerization into the 
microtubules (MTs). This mode of action is also shared with other natural agents. Therefore, there is a 
strong need to design and develop new natural analogs as antimitotic agents to interact with tubulin at 
sites different from those of Vinca alkaloids and taxanes [59]. 
Dolastatin 10, a linear pentapeptide containing several unique amino acid subunits (Figure 3A), was 
derived from the marine mollusk Dolabella auricularia; it is the most potent member of a large class 
of related peptides [60,61]. Bai et al. reported that Dolastatin 10 inhibited the growth of L1210 murine 
leukemia cells in culture [62]. Preliminary studies indicated that Dolastatin 10 causes formation of a 
cold-stable tubulin aggregate at higher drug concentrations. Dolastatin 10 strongly inhibits microtubule 
assembly, tubulin-dependent GTP hydrolysis [62], and the binding of Vinca alkaloids to tubulin. 
Dolastatin 10 prevents loss of the stabilizing effects on the colchicine binding activity of tubulin. A 
tripeptide segment of Dolastatin 10 also effectively inhibits tubulin polymerization and GTP hydrolysis. 
The tripeptide did not significantly inhibit either vincristine binding or nucleotide exchange [63]. Mar. Drugs 2011, 9 
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Figure 3. Chemical structures of  major marine peptides which affect the   
tubulin-microtubule equilibrium: Dolastatin 10 (A) and Vitilevuamide (B). 
 
Vitilevuamide, a bicyclic 13 amino acid peptide (Figure 3B), was isolated from  two marine 
ascidians,  Didemnum cuculiferum and Polysyncranton lithostrotum. Vitilevuamide was strongly 
positive in a cell-based screen for inhibitors of tubulin polymerization, displaying activity in vivo 
against P388 lymphocytic leukemia. Vitilevuamide exhibits non-competitive inhibition of Vinblastine 
binding to tubulin. Colchicine binding to tubulin was stabilized in the presence of Vitilevuamide. GTP 
binding was also found to be weakly affected by the presence of Vitilevuamide, suggesting the 
possibility that Vitilevuamide inhibits tubulin polymerization via an interaction at a unique site [64]. 
Some other peptides from marine sources, such as Diazonamide A [65,66], Scleritodermin A [67,68], 
Hemiasterlin [69–72], Desmethoxymajusculamide C (DMMC) [73] and Milnamide D [74] have been 
observed to display potent inhibition of tubulin polymerization in different cancer cells. Diazonamide A, 
a complex cytotoxic peptide, was isolated from the marine ascidian Diazona angulata [65]. 
Diazonamide A and the analog have a unique binding site on tubulin differing from the Vinca alkaloid 
and Dolastatin 10 binding sites. Diazonamide A and the analog bind weakly to unpolymerized tubulin 
but strongly to microtubule ends [65,66]. Scleritodermin A is a new cyclic peptide isolated from the 
lithistid sponge Scleritoderma nodosum. Scleritodermin A showed significant in vitro cytotoxicity 
against human tumor cell lines and inhibited tubulin polymerization [67,68]. Hemiasterlin, a natural 
tripeptide derived from marine sponges Auletta and Siphonochalina sp., binds to the Vinca-peptide site 
in tubulin, disrupts normal microtubule dynamics; depolymerize microtubules [69,70]. One analogue 
of Hemiasterlin, HTI-286, inhibits the polymerization of purified tubulin, disrupts microtubule 
organization in cells. HTI-286 is considered as a potent inhibitor of proliferation and has substantially 
less interaction with multidrug resistance protein (P-glycoprotein) than currently used antimicrotubule 
agents [71,72]. Desmethoxymajusculamide C (DMMC), a new cyclic depsipeptide was extracted from 
the Fijian Cyanobacterium Lyngbya majuscula. DMMC exhibited potent and selective anti-solid tumor Mar. Drugs 2011, 9 
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activity against the HCT-116 human colon carcinoma cell line via disruption of cellular microfilament 
networks. Linearized DMMC was also evaluated in the biological assays and found to maintain potent 
actin depolymerization characteristics while displaying solid tumor selectivity equivalent to DMMC in 
the disk diffusion assay [73]. 
We purified an antitumor protein from the coelomic fluid of Meretrix meretrix Linnaeus,   
MML, which exhibited significant cytotoxicity to several cancer cell types, including human hepatoma 
BEL-7402, human breast cancer MCF-7 and human colon cancer HCT-116 cells. Further studies 
demonstrated that MML increased cell membrane permenbility and inhibition of tubulin 
polymerization [75]. 
4. Peptides that Inhibit Angiogenesis 
Angiogenesis, the formation of new blood vessels, is a complex multistep process, including   
the destabilization of established vessel, endothelial cell proliferation, migration and new tube 
formation. Angiogenesis plays an important role in the growth, invasion and metastasis of most solid 
tumors. Both tumor growth and metastasis depend on the expansion of host vasculatures into tumors 
through angiogenesis [76–79]. Vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2 
(Flk-1/KDR), play a key role in tumor angiogenesis [80,81]. Tumor growth may be inhibited via 
blocking the VEGF-VEGFR-2 pathway and downstream intracellular signaling. These pathways 
include VEGF-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), 
serine/threonine protein kinase family protein kinase B (Akt), two tumor promoters CXC chemokine 
Receptor (CXCR4) and Hypoxia inducible factor 1alpha (HIF1α) [82,83]. HIF1α, a subunit of HIF1 
transcription factor, regulates not only adaptive responses to hypoxia, but also many cellular functions 
under normoxia. HIF1α induces VEGF aggregation, actions known to be important for cellular 
survival and endovascular differentiation [84,85]. 
Neovastat (AE-941) is a derivative of shark cartilage extract. Rather than being a specific 
monomolecular compound, AE-941 is a defined standardized liquid extract comprising the <500 kDa 
fraction from the cartilage of shark, Squalus acanthias, directly inhibits tumor cell growth and 
angiogenesis [86,87]. Lee et al. founded that Neovastat was mediated via inhibition of VEGF and 
HIF2 alpha pathway [88]. Mice treated with Neovastat had significantly reduced inflammatory cell 
count in BAL fluid. Furthermore, Mice treated with Neovastat showed significantly reduced VEGF 
and HIF2 alpha expression on lung tissue [88]. 
We purified a novel linear polypeptide with MW 15500, PG155, with potent anti-angiogenic 
activity from the cartilage of shark, Prionace glauca. The anti-angiogenic effects of PG155 were 
evaluated using zebrafish embryos model in vivo. Our study confirmed that PG155 inhibited the 
growth of SIV of zebrafish embryos. In vitro transwell experiment revealed that the polypeptide 
inhibited VEGF induced migration and tubulogenesis of human umbilical vein endothelial cells 
(HUVECs) [89]. 
Mycothiazole, a mixed polyketide/peptide-derived compound with a central thiazole moiety, 
inhibited hypoxic HIF1 signaling in tumor cells that correlated with the suppression of HIF1 target 
gene VEGF expression. Mechanistic studies revealed that mycothiazole selectively suppresses Mar. Drugs 2011, 9 
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mitochondrial respiration at complex I (NADH-ubiquinone oxidoreductase), may serve as a valuable 
molecular probe for mitochondrial biology and HIF-mediated hypoxic signaling [90]. 
5. Peptides with Unknown Mechanism for Their Anti-Tumor Activity 
Although a huge effort has been put on the development of anticancer agents from marine sources, 
this area is still a virgin field and many fewer peptides have been identified so far compared with the 
research on the peptides isolated from other natural sources. There are still many other peptides with 
unknown mechanisms for their induction of cytotoxicity, likely because they involve complicated 
mechanisms. A lot of peptides were isolated from ascidians, including patellamides [91–94],   
Styelin D [95], Eusynstyelamide [96], botryllamides A–D (1–4) [97], Lissoclinamides [46,98,99] and 
Mollamides [100,101] , which display potent cytotoxicity, but their exact mechanism have not been 
well documented. Styelin D, a 32-residue C-terminally amidated antimicrobial peptide, isolated from 
blood cells of the ascidian Styela clava is discovered a cytotoxic peptide, was quite cytotoxic and 
hemolytic to eukaryotic cells [95]. Lissoclinamides (Lissoclinamides 4 and 5), a cyclic peptide isolated 
from the aplousobranch ascidian Lissoclinum patella [98], showed relevant antineoplastic as well as 
other pharmacological properties against human fibroblast and bladder carcinoma cell lines and normal 
lymphocytes [46]. The most potent is Lissoclinamide 7, containing two thiazoline rings, which rivals 
Didemnin B in cytotoxicity in vitro [99]. 
Sponge is another rich resource of peptides, such as Geodiamolides A–G [102,103],   
Orbiculamide A [104], Koshikamide B [105], Phakellistatins [106–109], Microcionamides A and   
B [110], Halicylindramides [111], Haligramides [112], Hemiasterlin [113], Milnamide A [114],   
Corticiamide A [115], Theopapuamide [116], Taumycins A [117], Koshikamide A1 [118], 
Koshikamide A2 [119] and Efrapeptin G [120] have been observed to display potent cytotoxicity in 
different cancer cells but the exact targets by these chemicals have not yet been identified. 
Geodiamolides A–G initially isolated from the Caribbean sponge Geodia sp. are a group of cytotoxic 
peptides in which there is three amino acids forming a cyclic peptide with a common polyketide   
unit [102,103]. Orbiculamide A, acyclic peptide from a marine sponge Theonella sp., is cytotoxic 
against P388 murine leukemia cells (ED50 = 0.34 µg/mL), but also against different melanoma cell 
lines [104]. Koshikamide B, a cytotoxic peptide lactone from a marine sponge Theonella sp., is a  
17-residue peptide lactone composed of six proteinogenic amino acids, two D-isomers of proteinogenic 
amino acids, seven N-methylated amino acids, and two unusual amino acid residues. Koshikamide B 
exhibits cytotoxicity against P388 murine leukemia cells and the human colon tumor (HCT-116) cell 
line [105]. Phakellistatins, isolated from two Indo-Pacific sponges, Phakellia costata and Stylotella 
aurantium, are a group of proline rich cyclic heptapeptides; Phakellistatin 1, showed potent activity 
against P388 murine leukemia cells and other different melanoma cell lines [106]. Microcionamides A 
and B , new linear peptides cyclized via a cysteine moiety and isolated from the Philippine Sponge 
Clathria (Thalysias) abietina, exhibited significant cytotoxicity against the human breast tumor cells 
lines MCF-7 and SKBR-3 and displayed inhibitory activity against Mycobacterium tuberculosis 
H37Ra [110]. Similarly, several other marine anticancer peptides, including Keenamide A [121], 
Kulokekahilide-1 [122], Kulokekahilide-2 [123] and Scopularide A and B [124], also elicit antitumor 
activity via unknown mechanisms. Keenamide A, a new cytotoxic cyclic hexapeptide, was isolated Mar. Drugs 2011, 9 
 
 
1849
from the notaspidean mollusk Pleurobranchus forskalii. Keenamide A exhibited significant activity 
against the P388, A549, MEL-20, and HT-29 tumor cell lines [121].  
Some other antitumor peptides including Symplocamide A [125,126], Apratoxin D [127,128] and 
Mitsoamide [129] have been isolated recently from Cyanobacteria. Symplocamide A is a newly 
discovered 3-amino-6-hydroxy-2-piperidone (Ahp) cyclodepsipeptide, isolated from a marine 
cyanobacteria Symploca sp. in Papua New Guinea [126]. Symplocamide A is an extremely potent 
cytotoxin, with IC50 in nanomole level for H460 lung cancer and neuro-2A neuroblastoma cell   
lines [125]. Apratoxin D was extracted from marine cyanobacteria Lyngbya majuscula and Lyngbya 
sordida. Apratoxin D showed potent in vitro cytotoxicity against H-460 human lung cancer cells with 
an IC50 value of 2.6 nM [127]. Recently, a new cytotoxic and linear peptide was isolated from the 
marine cyanobacteria Geitlerinema sp. [129]. Additionally, two novel cyclodepsipeptides, 
Scopularides A and B were found in the fungus Scopulariopsis brevicaulis and activity of Scopularides 
against several tumor cell lines was significant at 10 µg/mL [124]. However, the exact mechanisms by 
these peptides have not yet been identified. 
6. Conclusions 
The discussed marine peptides and their mode actions are summarized in Table 1. However, a lot of 
marine peptides display antitumor activity via multiple targets. Dolastatin 10 not only inhibits 
microtubule assembly, but also induces apoptosis associating with a decrease in Bcl-2 level and an 
increase in p53 expression in the lymphoma cell line [130]. Aplidine’s mechanism of action involves 
several pathways, including cell cycle arrest, inhibition of protein synthesis and anti-angiogenic 
activity [131]. 
Table 1. A summary of marine peptides and their mode of actions. 
Name of peptides  Sources  Class/types  Mode of action and references 
Jaspamide 
(Jasplakinolide) 
Marine sponge, Jaspis johnstoni 
Cyclic 
depsipeptide 
Caspase-3 activation, decreasing in 
Bcl-2 protein expression [28–30] 
Somocystinamide A 
(ScA) 
Lyngbya majuscula/ Schizothrix sp. 
assemblage of marine cyanobacteria 
Lipopeptide  Caspase-8 activation [31,32] 
C-phycocyanin (C-PC) 
Cyanobacteria Agmenellum 
quadruplicatum, Mastigocladus 
laminosus, Spirulina platensis 
Tetrapyrrole-
protein complex 
Caspases-dependent apoptosis [34]
Aplidine 
(dehydrodidemnin B, 
DDB, Aplidin) 
Tunicate, Aplidium albicans 
Cyclic 
depsipeptide 
JNK and p38 MAPK 
phosphorylation activation [37–39]
Didemnin B  Tunicate, Trididemnum solidum 
Cyclic 
depsipeptide 
Apoptosis, but unclear [44–49] 
Sansalvamide A  Marine fungus 
Cyclic 
depsipeptide 
Apoptosis, but unclear [53,54] 
Cycloxazoline 
Marine ascidian,  
Lissoclinum bistratum 
Cyclic 
depsipeptide 
Apoptosis, but unclear [55,56] 
Virenamides A–C 
Didemnid ascidian,  
Diplosoma virens 
Linear tripeptides  Apoptosis, but unclear [57] Mar. Drugs 2011, 9 
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Table 1. Cont. 
Name of peptides  Sources  Class/types  Mode of action and references 
Dolastatin 10 
Marine mollusk,  
Dolabella auricularia 
Linear peptide 
Microtubule assembly  
Inhibition [60,62] 
Vitilevuamide 
Marine ascidians,  
Didemnum cuculiferum and 
Polysyncranton lithostrotum 
Bicyclic peptide 
Tubulin polymerization  
inhibition [64] 
Diazonamide Marine  ascidian,  Diazona angulata Macrocyclic  peptide 
Tubulin polymerization  
inhibition [65,66] 
Scleritodermin A 
Lithistid sponge, Scleritoderma 
nodosum 
Cyclic peptide 
Tubulin polymerization  
inhibition [67,68] 
Hemiasterlin 
Marine sponges, Auletta sp. and 
Siphonochalina sp. 
Tripeptide 
Tubulin polymerization  
inhibition [70–72] 
DMMC Cyanobacterium  Lyngbya majuscula Cyclic  depsipeptide 
Tubulin polymerization  
inhibition [73] 
MML Coelomic  fluid,  Meretrix meretrix Protein 
Tubulin polymerization  
inhibition [75] 
Neovastat (AE-941)  Shark cartilage, Squalus acanthias  Extract < 500 kDa 
VEGF and HIF2 alpha pathway 
inhibition [86–88] 
PG155 Shark  cartilage,  Prionace glauca Polypeptide 
VEGF induced angiogenesis 
inhibition [89] 
Styelin D  Ascidian, Styela clava 
C-terminally 
amidated peptide 
Unknown [95] 
Lissoclinamides 
Aplousobranch ascidian, Lissoclinum 
patella 
Cyclic peptide  Unknown [46,98,99] 
Geodiamolides A–G  Caribbean sponge, Geodia sp.  Cyclic peptide  Unknown [102,103] 
Orbiculamide A  Marine sponge, Theonella sp.  Cyclic peptide  Unknown [104] 
Koshikamide B  Marine sponge, Theonella sp.  Peptide lactone  Unknown [105] 
Phakellistatins  Marine sponges  Cyclic heptapeptides Unknown [106–109] 
Microcionamides A  
and B 
Philippine Sponge, Clathria 
(Thalysias) abietina 
Linear peptides  Unknown [110] 
Keenamide A 
Notaspidean mollusk, 
Pleurobranchus forskalii 
Cyclic hexapeptide  Unknown [121] 
Scopularides A and B  Fungus Scopulariopsis brevicaulis Cyclodepsipeptide  Unknown  [124] 
Symplocamide A  Marine cyanobacteria Symploca sp.  Cyclodepsipeptide  Unknown [125,126] 
Apratoxin D 
Marine cyanobacteria Lyngbya 
majuscula and Lyngbya sordida 
Macrocycle peptide  Unknown [127,128] 
Mitsoamide 
Marine cyanobacteria  
Geitlerinema sp. 
Linear peptide  Unknown [129] 
Peptide compounds reviewed here are obtained from very different marine organisms with different 
mechanism on their antitumor activity. Because of the peculiarities of the life in the sea, many of these 
molecules can be found only in a single source For example, Jaspamide (Jasplakinolide) is only found 
in marine sponge Jaspis species [28–30], and Trididemnum genus of marine tunicate is the only source 
for Didemnin B [44–49]. Although the underling mechanism of source specificity of the marine Mar. Drugs 2011, 9 
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peptides is unclear, it is conceivable that the special environment of marine offers the diversity of 
marine natural products. It is also possible that the organisms, which may contain the peptides, have 
not been found since the study of marine peptides is still in its infancy. Compared with the peptides 
found from other sources, there is more diversity on the style/classes of marine peptides; more cyclic 
peptides or depsipeptide were found in marine organism. These marine peptides seem to be very useful 
and promising for biomedical research. There is no doubt that the diversity of marine peptides in its 
structure and mode of action provide a rich source for the design of very specific and potent new 
pharmaceuticals for a wide variety of diseases.  
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